AltruBio

PRODUCT PIPELINE

• Product
  Indication

  • Preclinical
  • Phase I
  • Phase IIa
  • Phase IIb
  • Phase III
• Immunology Product - PSGL1:T-Cell Checkpoint Regulator Platform

• AbGn-168H Neihulizumab

  Psoriatic Arthritis

  • 100

  • 100

  • 100

  • 0

  • 0

  • Phase II

  Phase II Phase 2a Psoriatic Arthritis trial completed with proof of clinical efficacy achieved.

  Ulcerative Colitis

  • 100

  • 100

  • 100

  • 0

  • 0

  • Phase II

  Phase II Phase 2a anti-TNF α and/or anti-integrin refractory/intolerant Ulcerative Colitis trial completed with proof of clinical efficacy achieved; continued UC development planned with leiolizumab.

  Steroid Refractory Acute Graft Versus Host Disease

  • 100

  • 50

  • 0

  • 0

  • 0

  • Phase I

  Phase I Phase 1b multi-dose steroid refractory acute graft versus host disease trial ongoing

  Acute Graft Versus Host Disease

  • 100

  • 50

  • 0

  • 0

  • 0

  • Phase I

  Phase I Investigator sponsored Phase 1 front line acute graft versus host disease trial ongoing.

  Solid Organ Transplantation

  • 50

  • 0

  • 0

  • 0

  • 0

  • Phase I

  Phase I Renal Transplantation Non-Human Primate preclinical studies ongoing.

• AbGn-268 Leiolizumab

  Inflammation Disease

  • 80

  • 0

  • 0

  • 0

  • 0

  • Preclinical

  Preclinical Potency improved version of AbGn-168H for Chronic Inflammatory Disease